Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts

Cardiovascular Research

Volumn 115, Issue 10, 2019, Pages 1533-1545

  Uthman, Laween ^a   Nederlof, Rianne ^b   Eerbeek, Otto ^a   Baartscheer, Antonius ^a   Schumacher, Cees ^a   Buchholtz, Ninée ^a   Hollmann, Markus W ^a   Coronel, Ruben ^a   Weber, Nina C ^a   Zuurbier, Coert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Empagliflozin; Ischaemia; Isolated heart; Reperfusion; Sodium hydrogen exchanger

Indexed keywords

CARIPORIDE; EMPAGLIFLOZIN; ENIPORIDE; GLUCOSE 6 PHOSPHATE; INSULIN; LACTIC ACID; SODIUM PROTON EXCHANGE PROTEIN 1; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GUANIDINE DERIVATIVE; SLC9A1 PROTEIN, MOUSE; SULFONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRY WEIGHT; EX VIVO STUDY; GLYCOGEN ANALYSIS; HEART PERFUSION; HEART PROTECTION; HEART WEIGHT; IN VIVO STUDY; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; VOLKMANN CONTRACTURE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; HEART CONTRACTION; HEART INFARCTION; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; BENZHYDRYL COMPOUNDS; DISEASE MODELS, ANIMAL; GLUCOSIDES; GUANIDINES; INSULIN; ISOLATED HEART PREPARATION; MALE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SODIUM-HYDROGEN EXCHANGER 1; SULFONES; TIME FACTORS;

EID: 85068524092     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvz004     Document Type: Article

References (51)

1. Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017;60:568-573.
2. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 2018;61:722-726.
3. Packer M. Activation and Inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 2017;136:1548-1559.
4. Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: The sodium hypothesis. Cardiovasc Res 2018;114:12-18.
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
6. Neal B, Perkovic V, Mahaffey KW, Zeeuw D, de, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.
7. ten Hove M, Van EmousJG, Van Echteld, CJA. Na+ overload during ischemia and reperfusion in rat hearts: comparison of the Na+/H+ exchange blockers EIPA, cariporide and eniporide. Mol Cell Biochem 2003;250:47-54.
8. Hartmann M, Decking UKM. Blocking Na+-H+ exchange by cariporide reduces Na+overload in ischemia and is cardioprotective. J Mol Cell Cardiol 1999;31:1985-1995.
9. Karmazyn M. NHE-1: still a viable therapeutic target. J Mol Cell Cardiol 2013;61: 77-82.
10. Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemiainduced rise in cytosolic free calcium. Circ Res 1991;68:1250-1258.
11. Andersen AD, Bentzen BH, Salling H, Klingberg H, Kanneworff M, Grunnet M, Pedersen SF. The cardioprotective effect of brief acidic reperfusion after ischemia in perfused rat hearts is not mimicked by inhibition of the Na+/H+ exchanger NHE1. Cell Physiol Biochem 2011;28:13-24.
12. Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JT, Jessel A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000;102:3032-3038.
13. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schröder R, Tiemann R, Machnig T, Neuhaus K-L. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2001;38:1644-1650.
14. Mentzer RM, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, Haverich A, Knight J, Menasché P, Myers ML, Nicolau J, Simoons M, Thulin L, Weisel RD. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008;85:1261-1270.
15. Pedersen SF, King SA, Nygaard EB, Rigor RR, Cala PM. NHE1 inhibition by amilorideand benzoylguanidine-Type compounds: inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity. J Biol Chem 2007;282:19716-19727.
16. Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou PE, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 2017; 8:1077.
17. Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol 2018;236:69-84.
18. Yu Q, Zhou N, Nan Y, Zhang L, Li Y, Hao X, Xiong L, Lau WB, Ma XL, Wang H, Gao F. Effective glycaemic control critically determines insulin cardioprotection against ischaemia/reperfusion injury in anaesthetized dogs. Cardiovasc Res 2014;103:238-247.
19. Gumina RJ, Mizumura T, Beier N, Schelling P, Schultz JJ, Gross GJ. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 1998;286:175-183.
20. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009;46:821-831.
21. Garcia-Dorado D, Ruiz-Meana M, Inserte J, Rodriguez-Sinovas A, Piper HM. Calciummediated cell death during myocardial reperfusion. Cardiovasc Res 2012;94:168-180.
22. Sauvage M, Maziere P, Fathallah H, Giraud F. Insulin stimulates NHE1 activity by sequential activation of phosphatidylinositol 3-kinase and protein kinase C[zeta] in human erythrocytes. Eur J Biochem 2000;267:955-962.
23. Jonassen AK, Sack MN, Mjøs OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cellsurvival signaling. Circ Res 2001;89:1191-1198.
24. Nederlof R, van den Elshout MAM, Koeman A, Uthman L, Koning I, Eerbeek O, Weber NC, Hollmann MW, Zuurbier CJ. Cyclophilin D ablation is associated with increased end-ischemic mitochondrial hexokinase activity. Sci Rep 2017;7:12749.
25. Gurel E, Smeele KM, Eerbeek O, Koeman A, Demirci C, Hollmann MW, Zuurbier CJ. Ischemic preconditioning affects hexokinase activity and HKII in different subcellular compartments throughout cardiac ischemia-reperfusion. J Appl Physiol 2009;106: 1909-1916.
26. Zuurbier CJ, Eerbeek O, Meijer AJ. Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol 2005;289:496-499.
27. Nederlof R, Gürel-Gurevin E, Eerbeek O, Xie C, Deijs GS, Konkel M, Hu J, Weber NC, Schumacher CA, Baartscheer A, Mik EG, Hollmann MW, Akar FG, Zuurbier CJ. Reducing mitochondrial bound hexokinase II mediates transition from non-injurious into injurious ischemia/reperfusion of the intact heart. J Physiol Biochem 2016;73:323-333.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
29. Welle HF, ter Baartscheer A, Fiolet JW, Schumacher CA. The cytoplasmic free energy of ATP hydrolysis in isolated rod-shaped rat ventricular myocytes. J Mol Cell Cardiol 1988;20:435-441.
30. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res 1996;78:482-491.
31. Pasdois P, Parker JE, Halestrap AP. Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc 2012;2:e005645.
32. Smeele KMA, Southworth R, Wu R, Xie C, Nederlof R, Warley A, Nelson JK, Horssen P, Van Wijngaard JP, Van Den Heikkinen S, Laakso M, Koeman A, Siebes M, Eerbeek O, Akar FG, Ardehali H, Hollmann MW, Zuurbier CJ. Disruption of hexokinase II-mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis. Circ Res 2011;108:1165-1169.
33. Wu R, Smeele KM, Wyatt E, Ichikawa Y, Eerbeek O, Sun L, Chawla K, Hollmann MW, Nagpal V, Heikkinen S, Laakso M, Jujo K, Wasserstrom JA, Zuurbier CJ, Ardehali H. Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury. Circ Res 2011;108:60-69.
34. Andrienko TN, Pasdois P, Pereira GC, Ovens MJ, Halestrap AP. The role of succinate and ROS in reperfusion injury-A critical appraisal. J Mol Cell Cardiol 2017;110:1-14.
35. Garcia-Dorado D, González MA, Barrabés JA, Ruiz-Meana M, Solares J, Lidon R-M, Blanco J, Puigfel Y, Piper HM, Soler-Soler J. Prevention of ischemic rigor contracture during coronary occlusion by inhibition of Na+-H+ exchange. Cardiovasc Res 1997;35:80-89.
36. Ruiz-Meana M, Garcia-Dorado D, Juliá M, Inserte J, Siegmund B, Ladilov Y, Piper M, Tritto FP, González MA, Soler-Soler J. Protective effect of HOE642, a selective blocker of Na+-H+ exchange, against the development of rigor contracture in rat ventricular myocytes. Exp Physiol 2000;85:17-25.
37. Piper HM, Abdallah Y, Schäfer C. The first minutes of reperfusion: A window of opportunity for cardioprotection. Cardiovasc Res 2004;61:365-371.
38. Ruiz-Meana M, Garcia-Dorado D, Pina P, Inserte J, Agulló L, Soler-Soler J. Cariporide preserves mitochondrial proton gradient and delays ATP depletion in cardiomyocytes during ischemic conditions. Am J Physiol Heart Circ Physiol 2003;285:999-1006.
39. Jespersen NR, Lassen TR, Hjortbak MV, Stottrup NB, Botker HE. Sodium Glucose Transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates post-ischemic mitochondrial function. Cardiovasc Pharmacol Open Access 2017;6:2-4.
40. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PWM, Verma S, Dyck JRB. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2017; 2:347-354.
41. Hatanaka T, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 2016; 4:e00239.
42. Chang Y-K, Choi H, Jeong JY, Na K-R, Lee KW, Lim BJ, Choi DE. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016;11: e0158810.
43. Vaughan-Jones RD, Wu ML. Extracellular H+ inactivation of Na+-H+ exchange in the sheep cardiac Purkinje fibre. J Physiol (Lond) 1990;428:441-466.
44. Wu ML, Vaughan-Jones RD. Effect of metabolic inhibitors and second messengers upon Na+-H+ exchange in the sheep cardiac Purkinje fibre. J Physiol 1994;478: 301-313.
45. Hendrikx M, Mubagwa K, Verdonck F, Overloop K, Van Hecke P, Vanstapel F, Van Lommel A, Verbeken E, Lauweryns J, Flameng W. New Na+-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca21 overload in isolated perfused rabbit heart. Circulation 1994;89: 2787-2798.
46. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003;107:2850-2856.
47. Kingma JG. Inhibition of Na+/H+ exchanger with EMD 87580 does not confer greater cardioprotection beyond preconditioning on ischemia-reperfusion injury in normal dogs. J Cardiovasc Pharmacol Ther 2018;23:254-269.
48. Halestrap AP, Pereira GC, Pasdois P. The role of hexokinase in cardioprotection-mechanism and potential for translation. Br J Pharmacol 2015;172:2085-2100.
49. Nederlof R, Eerbeek O, Hollmann MW, Southworth R, Zuurbier CJ. Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemiareperfusion injury in heart. Br J Pharmacol 2014;171:2067-2079.
50. Peart J, Headrick JP. Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects. Cardiovasc Res 2003;58:589-601.
51. Toyoda Y, Friehs I, Parker RA, Levitsky S, McCully JD. Differential role of sarcolemmal and mitochondrial K(ATP) channels in adenosine-enhanced ischemic preconditioning. Am J Physiol Heart Circ Physiol 2000;279:H2694-H2703.